



Published in final edited form as:

Mol Pharm. 2011 August 1; 8(4): 1209–1223. doi:10.1021/mp200027z.

Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: formulation, *in-vitro* and *in-vivo* evaluation

Raghavendra S. Navath^{1,2,†}, Anupa R. Menjoge^{1,2}, Hui Dai^{2,3}, Roberto Romero², Sujatha Kannan^{2,3}, and Rangaramanujam M. Kannan^{1,2,*}

¹Department of Chemical Engineering and Material Science, and Biomedical Engineering, Wayne State University, Detroit, Michigan, 48202, USA

²Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, and Department of Health and Human Services, Detroit, MI 48201, USA

³Department of Pediatrics (Critical Care Medicine), Children's Hospital of Michigan, Wayne State University, Detroit, MI, 48201, USA.

Abstract

Local intravaginal drug therapy is preferred for treatment of ascending genital infections during pregnancy. In the present study, *in-situ* forming biodegradable hydrogel for sustained release of amoxicillin in the cervicovaginal region is described. A generation 4 poly(amidoamine) [G4-(NH₂)₆₄] dendrimer with peripheral thiopyridyl terminations is crosslinked with 8-arm polyethylene glycol (PEG) bearing thiol terminations. The hydrogels were formulated and tested *in-vivo* in pregnant guinea pig model for volume, retention times, biodegradation, tolerability and transport across fetal membrane. The physicochemical characterization of the hydrogels was carried out using differential calorimetry, SEM, and confocal imaging. The hydrogels offer antibacterial activity arising from sustained release of amoxicillin from gels. The *in-vivo* studies in guinea pig showed that 100-200 μ L of gel sufficiently covered the cervicovaginal region with a residence time of at least 72 h and gel was primarily retained in the maternal tissues without crossing the fetal membranes into the fetus. The dendrimer gels were stable upto 72 h and the *in-vivo* biodegradation of gel occurred after 72 h and this correlated well with the *in-vitro* degradation pattern. The pH of the vagina was not altered upon application of the gel and none of the animals aborted upto 72 h after application of gel. The histological evaluation of the cervical tissues showed absence of edema in epithelial cell layer, no sloughing of the epithelial or superficial mucous layer, absence of necrosis and infiltration of inflammatory cells in the submucosal layers confirmed that tissues were tolerant to the gel. The immunohistofluorescence images showed the localization of the gel components on the superficial mucified epithelial layer. The crosslinking density and swelling of hydrogels was impacted by the polymer content and the 10 % hydrogels exhibited highest crosslink density. The *in-vitro* drug release studies carried out using Franz diffusion cells showed that amoxicillin release from 6 and 10 % gels was sustained for 240 h as compared to 3 % gels. As the polymer concentration increased to 10 % the release pattern from gels approached diffusion controlled mechanism with diffusional exponent $n = 0.49$. In conclusion, the biodegradable *in-situ* forming hydrogels of present study offer a therapeutic option

*Corresponding author: ¹Department of Chemical Engineering and Material Science, and Biomedical Engineering, Wayne State University, Detroit, Michigan 48202; rkannan.wsu@gmail.com.

[†]Author current address: Ethicon Inc., Johnson & Johnson family of companies, Somerville, NJ08876

Supporting Information Available: Experimental procedures, ¹H NMR, ¹³C NMR, MALDI-TOF, analysis of all products are provided. This material is available free of charge via the Internet.

to provide sustained localized delivery of amoxicillin intracervically to the pregnant woman for the treatment of ascending genital infections.

Keywords

Injectable hydrogels; biodegradable hydrogel; sustained release of amoxicillin; pregnant guinea pig model; pregnancy; treatment of genital infections; formulation; *in-vitro* and *in-vivo* evaluation

1. Introduction

Hydrogels have found varied applications such as molecularly engineered scaffolds for controlled drug release, cellular delivery, tissue engineering and as wound dressings due to the highly hydrated and three dimensional properties which are similar to the native extracellular matrix (ECM)[1]. Hydrogels have attracted a great deal of attention as a matrix for the controlled delivery of biologically active substances [2]. The suitability of hydrogels for the pharmaceutical applications is mainly determined by their mechanical properties, drug loading and controlled drug release capability [3]. *In-situ* forming gels have been investigated for a varied applications such as oral, nasal, ocular, injectable, vaginal and rectal [4-7]. Thermosensitive gels are commonly investigated for the vaginal delivery of therapeutic agents as they gel in response to the body temperature. Thermosensitive vaginal gels for delivery of cotrimazole were formulated using Pluronic F127 [6]. Polycarbophil hydrogels were investigated for intravaginal delivery of granulocyte-macrophage colony-stimulating factor (GM-CSF) for treatment of human papillomavirus (HPV)-associated genital (pre)neoplastic lesions [8].

Over the years, the intravaginal route of drug administration has emerged as an effective means for local delivery of antibacterials, antifungals, antiprotozoals and antiviral agents [9]. The use of topical microbicides is common in pregnant women to treat yeast and bacterial infections. Bacterial vaginosis (BV) is found in 15-20% of pregnant women and it is an ascending genital tract infection of chorioamnion and amniotic fluid [10, 11]. Intrauterine infection during pregnancy is often responsible for disease causing spontaneous preterm birth and the infection which is associated with the microorganisms ascending from vagina and cervix is known to affect the fetal membranes and the cervical mucosa and endometrium [11]. Local drug delivery to cervical tissues is preferred. To treat BV in pregnant women antibiotics are administered intra-vaginally and the intravaginal route is preferred to attain high local drug concentration in the vagina, which cannot be achieved by oral administrations [12]. One major problem associated with intravaginal and intrauterine drug delivery is limited contact time of administered dosage form with the mucosa due to the physiological conditions imposed by the protective mechanisms of the cervix and vagina [6, 8]. This reduces the therapeutic efficacy and necessitates frequent dosing [6, 13, 14]. Gels are better tolerated than other conventional dosage forms [15, 16].

Dendrimer based intravaginal gels are extensively investigated as topical microbicides [17]. Polylysine dendrimer SPL7013 exhibited antimicrobial activity against herpes simplex virus [18] and its formulation development into a prototype acidified carbopol gel for intravaginal delivery was evaluated in animal models [19-21]. Human clinical trials (Phase I and II) were conducted to determine the retention, duration of activity, safety and tolerability of a gel containing SPL7013 applied intravaginally to young non-pregnant women [22] and the gel was found to be safe and well tolerated [17, 19]. Further trials are being conducted to test its efficacy against genital herpes and HIV. Apart from SPL7013, the amine terminated PAMAM dendrimers are found to exhibit antibacterial activity towards gram-ve bacteria [23-25]. PAMAM dendrimer with hydroxyl terminations was found to effectively inhibit

intrauterine *Escherichia coli* (E. Coli) infections in guinea pigs [25]. Dendrimers are also used as carriers for the antimicrobial agents (*e.g.* triazine antibiotics) [26]. Quinolone drugs encapsulated in PAMAM dendrimers are highly active when used as topical microbicidal agents [27]. The silver complexes and nanocomposites with PAMAM dendrimer result in increased antibacterial activity towards the *S. aureus*, *P. aeruginosa* and *E. coli* [28]. Further, dendrimers are also extensively evaluated in several gel formulations [29-31]. Many polymers are currently evaluated as topical microbicides or as a component of the topical microbicide formulations to be applied on the vagina or rectal mucosa [9, 32].

In the present study, we have investigated the *in-situ* forming biodegradable hydrogels obtained by crosslinking of thiopyridyl functionalized PAMAM dendrimer [(NH₂)₄₉-G4-(NH-PDP)₁₅] with 8-arm polyethylene glycol (20 kDa) for sustained intravaginal delivery of amoxicillin to treat ascending genital infections during pregnancy. Multiple thiopyridyl surface functionalities of the dendrimer and the star-PEG are utilized to create a biodegradable gel with disulfide linkages. This offers the potential for the dendrimer and drug to be released, as the hydrogel degrades. Further, the dendrimers offer the potential to target selectively inflammatory cells [33]. The hydrogels were investigated for biodegradation, retention, tolerability and volume of distribution by intravaginal application in the pregnant guinea pig model. In the past hydrogels containing dendritic materials obtained by photocrosslinking, radiation, thermal gelation, ion interactions and freeze thaw cycles of polymers have been described [31, 34-38]. The hydrogels of the present study are formed *in-situ* by chemical crosslinking resulting from simple mixing of the [(NH₂)₄₉-G4-(NH-PDP)₁₅] dendrimer and the PEG polymer solutions in buffer through the formation of disulfide bonds and these hydrogels possess the properties of both the PEG hydrogels and the dendrimer.

The cervical infections in pregnant women caused by pathogens such as *Streptococcus group B*, *E. coli* and *Gardnerella vaginalis* are responsible for the premature rupture of the fetal membranes, chorioamnionitis and prematurity [39]. PAMAM dendrimer with amine terminations exhibits antibacterial activity against *E. coli*, *P. aeruginosa* and *S. aureus* [23, 24] by formation of nanoscale holes in lipid bilayers of bacterial cell membrane causing cell lysis [25]. The partially PEGylated amine terminated PAMAM dendrimers exhibit antibacterial activity against *E. Coli* bacteria, *P. aeruginosa* [23, 24]. The PEGylation of dendrimers reduces their cytotoxicity [17, 40] and yet retains the antibacterial activity [23, 24]. *In-situ* forming hydrogels from dendrimers with multifunctional groups was recently reported by our group [41]. In the present manuscript, the amine terminated PAMAM dendrimers are partially modified to thiopyridyl terminations which are chemically linked to the 8-arm-PEG by disulfide bridges to form the hydrogel while few of the amine groups are retained unmodified. The covalent linking of PEG to dendrimer while gel formation was expected to overcome the cytotoxicity. Further, the amoxicillin loaded hydrogels of this study are expected to exhibit dual acting mechanism towards the bacteria, arising from sustained release of the antibiotic and antibacterial activity exhibited by the amine terminated dendrimer released from the degrading gel. The present manuscript discusses the influence of formulation additives on the gel retention times, role of humectant to avoid gel dehydration and enhancement in gel adhesive properties.

2. Materials and methods

2.1. Materials

Amine terminated, ethylenediamine-core poly(amidoamine) dendrimer [G4-(NH₂)₆₄] (diagnostic grade generation-4 with -NH₂ groups) was purchased from Dendritech and 8-arm-PEG-SH (20 kDa) (**5**) was purchased from NOF America Corporation, USA. Other reagents were obtained from assorted vendors in the highest quality available. Of these,

amoxicillin, N-Succinimidyl 3-(2-thiopyridyl)-propionate (SPDP), polyvinylpyrrolidone (PVP 30 kDa), PEG 600, glycerol, glutathione (GSH), dimethyl sulfoxide (DMSO), fluorescein isothiocyanate (FITC), dimethylformamide (DMF), ethanol, phosphate buffer saline (PBS, pH, 7.4), and HPLC-grade solvents were obtained from Sigma-Aldrich.

2.2. Preparation of [(NH₂)₄₉-G4-(NH -PDP)₁₅] (4)

[G4-(NH₂)₆₄] (2) dendrimer (500 mg, 0.0351 mmole) was dissolved in PBS buffer pH 7.4 (20 mL) and the solution of SPDP (3) (351 mg, 1.126 mmole) in ethanol (10 mL) was added to it under stirring to provide sufficient modification whilst preventing loss of product due to the insolubility of highly modified dendrimer. Reaction was stirred at room temperature for 2h. After completion of the reaction, solvent was removed under reduced pressure to get a solid compound. The crude product obtained from the reaction mixture was purified by dialysis using spectrapor dialysis membranes (MW cut-off 1000 Da) against water (pH = 5 on addition of 1% HCl) changing the solvent every 8 h for 24 h to remove by-products and the excess of reactants. After dialysis, the solvent was removed using lyophilization to get pure compounds with yield of 78% (458 mg, 0.0274 mmole). Solid was reconstituted in desired amount of PBS (pH 7.4) and used for hydrogel formulation.

2.3. Preparation of [(NH₂)₄₇-G4-(NH-FITC)₂(NH -PDP)₁₅]

FITC (0.082g, 0.210 mmole) was added to the solution of [G4-(NH₂)₆₄] dendrimer (1gm, 0.070 mmole) in DMSO (20 mL) under stirring and the reaction was continued in dark for 18h. To remove unreacted FITC, the reaction mixture was dialyzed (membrane molecular weight cut off 1000Da) in DMSO for 24h changing DMSO every 8 hours. After dialysis the DMSO was lyophilized to get pure [(NH₂)₆₂-G4-(NH-FITC)₂] conjugate as dark orange color solid in 81% yield (0.854g, 0.0569 mmole). The [(NH₂)₆₂-G4-(NH-FITC)₂] conjugate was dissolved into methanol and precipitated in acetone. Absence of free FITC in the conjugate was verified by TLC using chloroform and methanol (ratio 1:1) as mobile phase. After purification of the [(NH₂)₆₂-G4-(NH-FITC)₂] conjugate the number of FITC molecules in [(NH₂)₆₂-G4-(NH-FITC)₂] was calculated based on ¹H-NMR and MALDI-TOF(data not shown), the above described procedure was used to prepare [(NH₂)₄₇-G4-(NH-FITC)₂(NH-PDP)₁₅] for hydrogel formulation for *in-vivo* applications.

2.4. Hydrogel formation

Hydrogels were prepared by crosslinking of the branched thiol terminated PEG polymer (8-arm-PEG-SH, 20 kDa) with [(NH₂)₄₉-G4-(NH-PDP)₁₅] (or [(NH₂)₄₇-G4-(NH-FITC)₂(NH-PDP)₁₅]). Hydrogels containing 10, 6 and 3 % w/v of polymers were prepared by mixing equal volumes (1:1 v/v, 100 μL each) of the 10, 6 and 3 %w/v polymer solutions of [(NH₂)₄₉-G4-(NH-PDP)₁₅] and 8-arm-PEG-SH in PBS (pH=7.4) as shown in Table 1. The ratio of PDP to thiol functionalities in these hydrogels was 2:1. The hydrogels resulted in 10-30s of mixing the two polymer solutions. The gelation time was determined by the vial tilting method [41]. When the sample showed no flow, it was considered as a gel. These hydrogels were further investigated to determine the degree of swelling, drug loading efficiency, *in-vitro* release studies, and *in-vivo* applications.

2.5. Morphology of the hydrogel

Scanning Electron Microscopy (SEM) analyses were performed to investigate the morphology of hydrogel. The 10, 6 and 3 % w/v hydrogels were prepared for electron microscopy at room temperature, followed by dehydration using lyophilization. It was observed that the hydrogel volume was reduced by ~75% during the dehydration process. The samples were critical point dried, sputter-coated with 9 nm of gold/palladium, and imaged using SEM (HITACHI S-2400 Scanning Electron Microscope) at 20 kV. The cross

sections of the hydrogels were observed using confocal microscopy, to determine the crosslink density. The gels were formed by crosslinking of $[(\text{NH}_2)_{47}\text{-G4-(NH-FITC)}_2(\text{NH-PDP})_{15}]$ with 8-arm-PEG-SH in PBS (pH=7.4). The 10, 6 and 3 % w/v gels were embedded in OCT media (Tissue-Tek®) and frozen at -80°C until they were sectioned. Gels sections (20 μ thick) were cut using a cryostat (Leica Microsystems; Nuchloss, Germany). Images of the sectioned gels were captured on a Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany).

2.6. Equilibrium swelling of hydrogels

The 10, 6 and 3 % w/v hydrogel discs were obtained by crosslinking of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and PEG (1:1v/v, 100 μL each) in a cylindrical glass vial (12 \times 35mm). These hydrogel discs were weighed and subsequently immersed in 5 mL of phosphate buffered saline (PBS, pH 7.4) solution at 37°C in 30 mL scintillation vials. The swollen hydrogels were removed from PBS and weighed at various time intervals until a swelling equilibrium had been reached. All experiments were carried out in triplicate and the results are expressed as means \pm standard deviations.

The degree of swelling was calculated from the formula previously reported [42] where W_s is the weight of the swollen hydrogel at time t and $W_0(\text{wet})$ is the initial weight.

$$\% \text{Swelling} = \frac{W_s - W_o}{W_o} \times 100$$

2.7. Formulation of hydrogel

The prototype vaginal gels were made using excipients; glycerin (5 %, v/v), PVP (4 %, w/w) and PEG 600 (5 %, v/v), which were included in hydrogel formulation to improve the emollient, adhesion, retention and spreadability properties of hydrogels. These excipients were dissolved in the PBS buffer at the concentrations mentioned above and this solution was used as a vehicle to dissolve separately the $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ (or $[(\text{NH}_2)_{47}\text{-G4-(NH-FITC)}_2(\text{NH-PDP})_{15}]$) and 8-arm-PEG-SH. The hydrogel formulation was obtained by mixing the solution of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and 8-arm-PEG-SH in the solvent vehicle at the ratio 1:1 v/v. The gelling time was recorded for the different compositions of vehicle and polymers. The optimal concentration of additives was determined by measuring the crosslinking time and retention time of hydrogel formulation on targeted area.

2.8. Reverse Phase HPLC characterization

In-vitro drug release and characterization of conjugates was carried out using a waters HPLC instrument equipped with one pump, an auto sampler and dual UV, RI, and fluorescence detector interfaced to millennium software. The mobile phase used was acetonitrile (both 0.14% TFA by w.) and water phase had a pH of 2.25. Mobile phases were freshly prepared, filtered and degassed prior to the use. Supelco Discovery BIO Wide Pore C5 HPLC Column (5 μm particle size, 25 cm \times 4.6 mm length \times I.D.) equipped with C5 Supelguard Cartridge (5 μm particle size, 2 cm \times 4.0 mm length \times I.D.) was used for characterization of the conjugates as well as *in-vitro* drug release studies. Gradient elution was used for analysis water: acetonitrile (100:0) to water-acetonitrile (60:40) in 25 minutes followed by returning to initial conditions for 5 minutes. The flow rate was 1 mL/min. Calibration curves were prepared for amoxicillin, based on UV absorbance peak area at 229 nm. These calibration curves were used for estimation of *in-vitro* drug release across cellulose membrane using Franz diffusion cells.

2.9. Differential scanning calorimetry (DSC) analysis of hydrogels

The neat, modified polymers and hydrogels were subjected to thermal analysis using TA Instruments DSC Q2000 V24.4 Build 116 Module DSC Standard Cell RC. The experiments were conducted in crimped sealed aluminium pans and the weight of each sample was in the range of 1–2 mg. All the samples were analyzed using the heat cool heat cycles. The samples were equilibrated at $-50\text{ }^{\circ}\text{C}$ for 2 min and were heated to $150\text{ }^{\circ}\text{C}$ at a heating rate of $5\text{ }^{\circ}\text{C}/\text{min}$ under nitrogen flow. The samples were quench cooled to $-50\text{ }^{\circ}\text{C}$ and equilibrated for 2 min and again heated to $150\text{ }^{\circ}\text{C}$ at a heating rate of $5\text{ }^{\circ}\text{C}/\text{min}$.

2.10. Degradation of hydrogels

In-vitro degradation of hydrogel was performed in glutathione (GSH) solutions at pH 4 and simulated vaginal fluid up to 72 h. The simulated vaginal fluid (SVF) was prepared as described previously [43] with the addition of GSH. Briefly, the SVF was prepared by dissolving 350 mg of NaCl, 140 mg of KOH, 22 mg of $\text{Ca}(\text{OH})_2$, 18 mg of bovine serum albumin, 200 mg of lactic acid, 100 mg of acetic acid, 16 mg of glycerol, 40 mg of urea, 500 mg of glucose, 20 mg of GSH in distilled water and the pH was adjusted to 4 ± 0.02 using 0.1 M HCl. Hydrogel discs obtained by crosslinking of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and 8-arm-PEG-SH (1:1v/v, 100 μL each) were immersed into the 5 mL GSH solution at pH 4 and simulated vaginal fluid at pH 4 in 30 mL scintillation vials in triplicate and observed for degradation. The GSH solutions in which hydrogels were immersed were injected into the HPLC system using an Ultrahydrogel size exclusion column and analyzed for the generation of different molecular weight components.

2.11. Drug loading into the hydrogels

Antibiotic (amoxicillin) was physically entrapped into the hydrogels. The drug (0.5 mg) was added to the PEG solution (100 μL) in vehicle and the solution of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ (100 μL) in vehicle was added to this PEG solution to form the 3%, 6%, 10% dendrimer-PEG hydrogel (200 μL) (Table 1).

2.12. Drug loading efficiency

The amount of amoxicillin entrapped in the dendrimer-PEG hydrogels (10%, 6% and 3%) was determined by breaking the gel into small pieces and transferring into 1 mL eppendorf tube filled with PBS (pH 7.4) and sonicated for 10 min. The hydrogel pieces were washed three times to extract drug. The washings were collected and filtered with 0.2 μm millipore filter and quantified by reverse phase (RP) HPLC analysis, monitoring elution at a wavelength of 229 nm. Water: acetonitrile were used as mobile phase at a flow rate of 1 mL/min. The difference between the amount of drug taken initially and the drug content in the washings is the amount of drug entrapped.

2.13. *In-vitro* drug release using Franz diffusion cell

For the *in-vitro* drug release study, jacketed Franz diffusion cells with flat ground joint were used. The use of Franz diffusion cell to test *in-vitro* drug release from topical or mucosal formulation is an accepted method [44-46]. The membrane was clamped between the donor and receiver chambers of the Franz diffusion cell apparatus with a diameter of 5 mm and a diffusional area of 0.64 cm^2 and the receptor chamber volume of 5 mL. Nitrocellulose acetate membranes (Millipore, America) with an average pore size of 0.45 μm were used. The receptor chambers filled with PBS (pH = 7.4) were maintained at $37\text{ }^{\circ}\text{C}$ in order to ensure the body temperature. Drug (Amoxicillin) is well soluble in the chosen receptor medium. Each cell contained a magnetic bar and was stirred (600 rpm) during the experiment and the cells were equilibrated for 1 h before the samples were mounted. 200 μL samples were taken at predetermined time points and replaced with equal amount of fresh

receptor medium to maintain sink condition. The samples were kept frozen at 4°C prior to analysis. Quantification of drug release was carried out by reverse phase high performance liquid chromatography (RP-HPLC). All samples were run in triplicates for statistical analysis.

2.14. Evaluation of hydrogel in pregnant guinea pig model

All the animal experimental procedures were approved by the institutional animal care and use committee of Wayne State University. Briefly, pregnant Dunkin-Hartley strain guinea pigs (n =15) (Charles River) at 55 days of gestation (third trimester) were anesthetized by inhalation of 5.0% Isoflurane in 100 % oxygen at a flow rate of 2 L/min in an approved rodent anesthesia chamber. Surgical-level of anesthesia was maintained with 1.5 and 2.0% Isoflurane in 100% oxygen at a flow rate of 1–2 L/min via a nose cone. An endoscope was used to visualize the cervix. FITC labeled dendrimer-PEG hydrogel (100-500 µL) was injected into the cervix using i.v. catheter (BD Angiocath, Infusion, Therapy systems Inc. SandyUtah, 16GA 5.25IN, 1.7× 133mm). The pH of the vagina was intermittently tested by wiping the vaginal fluid using cotton swabs. After single vaginal application, the vaginal cavity was observed for any signs of possible irritation of the vaginal mucosa (edema or redness of tissue). The observations were scored and recorded as follows: no erythema, slight erythema (light pink) and moderate to severe erythema (dark pink or light red). After 5, 12 24 and 72 h intervention, guinea pigs were euthanized with pentobarbital sodium (120 mg/kg) and midline laparotomy was performed to expose cervicovaginal region for further evaluation. The retention times, biodegradation and tolerability were studied *in-vivo* using the guinea pigs. The vaginal and cervical tissues were used for histopathological evaluation.

2.15. Immunofluorescence histochemistry

An immunofluorescence study was performed to investigate biodistribution of the FITC-dendrimer-PEG hydrogel in the cervicovaginal tissues of guinea pig after 24 and 72 h of treatment. Double immunofluorescent staining was performed on 20 µm thick, paraffin sections of tissues placed on silanized slides. The mucified epithelial cells were identified based on the positive staining for cytokeratin. The immunofluorescent staining was performed using Ventana Discovery autostainer for controlled and optimised reaction environment using the automation-optimized reagents from Ventana Medical Systems Inc. Briefly, paraffin wax sections were loaded onto the Ventana Discovery platform and following steps were completed automatically, these included dewaxing by EZ prep buffer (Ventana Medical Inc.), pre-treatment in Tris/EDTA pH 8.0 antigen retrieval solution (Ventana mCC1) or protease solution for 1 h (Ventana protease 2). Endogenous peroxidase was inactivated using an enhanced inhibitor provided in the staining kit and nonspecific antibody binding was blocked by treatment with blocking solution for 10 min. The blocking solution was removed and the sections were washed three times with PBS/Tween solution incubated with primary antibodies for 1 h using the liquid cover slip (Ventana Medical Inc). The primary antibody used was monoclonal mouse anti-human cytokeratin (1:200, M7018, Dako Carpinteria, CA, USA). The sections were again washed three times with PBS/Tween solution incubated with secondary antibodies, Alexa Fluor®594 goat anti-mouse IgG (1: 500, A11005, Invitrogen) for 1 h using the antibody diluent from Ventana. The sections were washed with PBS/Tween, counterstained and mounted with DAPI prolong Gold antifade and cover slipped. Images were captured from Leica TCS SP5 Laser Scanning Confocal Microscope (Leica Microsystems GmbH, Wetzlar, Germany). All study specimens were analyzed by a pathologist blinded to the clinical information.

3. Results and discussion

3.1. Synthesis and characterization of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$

To incorporate the thiol reactive terminal groups on the amine terminated PAMAM dendrimers to form hydrogel with 8-arm-PEG-SH, the heterobifunctional cross-linker linker SPDP was appended to the dendrimer to yield thiopyridyl functionalities (Scheme-1). The *N*-succinimidyl activated ester of SPDP was coupled to the terminal amine groups to form amide-linked 2-pyridyldithiopropanoyl (PDP) groups $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ (Scheme-1). The NMR analysis of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ (Fig. S1 supporting information) showed presence of protons corresponding to the aromatic ring of thiopyridyl groups and the dendrimer. The protons for aromatic ring of thiopyridyl appear at 7.20-2.26 (m, 1H, Ar), 7.74-7.82 (br.d, 1H, Ar), and 8.15-8.22 (m, 2H, Ar) ppm while the other protons appeared at 2.42-2.50 (m, 4H, $-\text{CH}_2\text{-CH}_2\text{-from PDP}$), 2.67-2.72 (m, 2H, $-\text{CH}_2\text{-from interior dendrimer}$) 2.86-2.92 (m, 1H, $-\text{CH}_2\text{-from interior dendrimers}$), 3.03-3.12 (m, 1H, $-\text{CH}_2\text{-from interior dendrimers}$) 8.38-8.45 (br.d, 1H, NH, from interior amide protons), and 8.52-8.59 (br.d, 1H, NH, from interior amide protons) ppm as seen from the ^1H NMR of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$. The number of PDP in $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ was calculated based on ^1H NMR analysis of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$. The integral ratio of the amide protons of dendrimer in $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ at 8.38-8.45, and 8.52-8.59 to the aromatic protons of thiopyridyl in $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ at 7.20-2.26, 7.74-7.82, and 8.15-8.22 suggests that $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ conjugate contains an average of 15 PDP moieties. These results are consistent with the MALDI-TOF (Fig. S2 supporting information) analysis which shows molecular mass increase from 13.75 kDa to 16.70 kDa upon conjugation of PDP groups to the dendrimer (see supporting information). The $[\text{G4-(NH}_2)_{64}]$ dendrimer showed a T_g at -28°C and this result is in accordance with that reported previously [44]. $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ showed T_g at 21.4°C and in addition it also exhibited an endotherm at 109.6°C (Fig. 1). The difference in the T_g between neat $[\text{G4-(NH}_2)_{64}]$ and $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ is attributed to the PDP groups appended on the dendrimer. The appearance of endotherm in $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ which was absent in neat $[\text{G4-(NH}_2)_{64}]$ dendrimer further confirms the addition of PDP groups to the dendrimer. These observations were consistent with those reported in the previous results [47, 48]. This $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ crosslinker was used to form dendrimer-PEG hydrogel with $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and 8-arm-PEG-SH. The partial modification of PAMAM $\text{G4-(NH}_2)_{64}$ dendrimer with amine terminations into $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ was carried out to enable the linking of PEG chains to the dendrimer by formation of disulfide bond.

3.2. Hydrogel formation

In-situ forming hydrogels with disulfide crosslinks were investigated for intravaginal delivery. Hydrogels incorporating 3, 6 and 10 % w/v of the polymer compositions were formed by mixing the solutions of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and 8-arm-PEG-SH, resulting in covalent disulfide crosslinks arising from the interaction of thiol groups of the PEG with the thiopyridyl functionalities on the dendrimer surface $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ (Table 1). The hydrogel results from intermolecular crosslinking as shown in Scheme-1. For the formation of hydrogels, the crosslinking agent $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ was used in an excess of molar ratio (in terms of the functional groups) relative to PEG-SH (Table 1). The hydrogel formation was confirmed by the inverted tube method. The hydrogels were formed in 10-30 sec of mixing the crosslinker and PEG solution in the upright tubes, and gel once formed was no longer pourable as seen from the inverted tubes in Fig. S3 (supporting information). The increase in polymer concentration impacts the rate of gel formation which was higher for higher polymer concentrations (Table 1). The rapid formation of hydrogels with the increased concentration of polymers might be due to formation of rapid and intense crosslinking networks, reducing the time for gelation. For example 10% hydrogel forms in

less than 10s, while the 3% hydrogel takes nearly 30s. Hydrogels appeared to be transparent, with uniform surface. The hydrogels were designed to facilitate the linking of PEG chains on the partially modified [(NH₂)₄₉-G4-(NH-PDP)₁₅] dendrimer. The linking of the PEG chains by disulfide bond formation further serves to overcome the cytotoxicity of the amine terminated dendrimer. PEGylation of dendrimers to overcome cytotoxicity is well documented [17, 40] and our *in-vivo* studies discussed in subsequent sections show that the gels were tolerant without any toxic effect.

3.3. Morphology of the hydrogel

Scanning electron microscopy (SEM) experiments were performed to study the surface morphology of dendrimer-PEG hydrogel (Fig. 2). SEM micrographs of critical point dried gels show a uniform dense structure with striations. The SEM experiments were performed on a dehydrated sample that exhibited significant reduction in volume from the hydrated state. It is likely that the water hydrated dendrimer-PEG hydrogel adopts a dense structure with regular crosslinking network throughout the gel. The cross section of the hydrogels was investigated by crosslinking the [(NH₂)₄₇-G4-(NH-FITC)₂ (NH-PDP)₁₅] and 8-arm-PEG-SH. The cross section observed under the confocal microscopy shows an isotropic hydrogel that exhibits a classic uniform morphology with pores as seen in Fig. 3. A characteristic change in morphology based on changes in polymer content in the hydrogel was observed (Fig. 3). The 3% hydrogel does not form a dense crosslinked network as seen for the 6 and 10 % gels. By introducing the different concentration PEG and dendrimer in the hydrogels, the porosity of the network changed, pore size is gradually decreased by increasing the concentration of polymer. These results suggest that dehydration of gels for SEM leads to artifact in the highly water-saturated gels, their morphology can be better viewed by cryo-sectioning the gels with the presence of fluorescein isothiocyanate (FITC).

3.4. Effect of formulation additives

The [(NH₂)₄₉-G4-(NH-PDP)₁₅] and 8-arm-PEG-SH crosslinked hydrogels were formulated with glycerin (5 %, v/v), PVP (4 %, w/v) and PEG 600 (5 %, v/v). The effect of formulation additives on the gelation time was investigated as shown in Table S1. The concentration of PVP was found to affect the gelation time and at higher concentration (8% w/v) the gels took longer than 50 sec to form hence its concentration less than 8%w/v was considered in formulation. The concentration of PEG 600 and glycerin did not significantly affect the gelation time. The vaginal musoca is moist and at any given time the volume of the vaginal fluid is less than 1 mL and there is a possibility of fluid being reabsorbed [49]. The hydrogels of the present study will be placed in an environment with relatively low water content. The formulation additives were incorporated in the hydrogel to prevent it from becoming brittle and dehydrated. Glycerin and PEG 600 was incorporated in the hydrogels as these act as humectant and help maintain the gels in plasticized supple form [51-53]. The humectant properties of glycerin and PEG 600 are well known. PVP was incorporated in the gel to provide mucoadhesive property and to increase the viscosity of the gel forming solutions to prevent their leak outside the cavity during instillation and formation of crosslinked hydrogels [54]. Use of PVP in vaginal gels for enhancing the mucoadhesive properties is well known [6, 55-58]. The optimal concentration of the additives to prevent brittleness and increase retention time on vaginal mucosa for upto prolonged periods of time was found to be glycerin (5 %, v/v), PVP (4 %, w/w) and PEG 600 (5 %, v/v).

3.5. Thermal analysis

The thermal behavior of the dendrimer-PEG hydrogel components and the hydrogel was investigated by DSC analysis. The DSC thermograms of dendrimer-PEG hydrogels, [(NH₂)₄₉-G4-(NH-PDP)₁₅], 8-arm-PEG-SH, are shown in Fig. 4A. 8-arm-PEG-SH exhibits an endotherm at 51.7°C (Fig. 4e). The T_g of [G4-(NH₂)₆₄] dendrimer was -28°C and

$[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ showed the presence of an endothermic peak at 109.3 °C with a T_g at 21.4°C (Fig. 4a). The DSC profiles show that after dendrimer was converted to its PDP derivative, the T_g shifted, indicating an altered polymer microstructure. When comparing the profiles of $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and 8-arm-PEG-SH, the crosslinking of the two polymers clearly produced a new material having a microstructure different from either of its two components. In case of hydrogels the T_g was found to be higher than that observed for the $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$, e.g. the 3 % hydrogel exhibited a T_g of 34.7°C and the 10% and 6% hydrogels exhibited a T_g at 35.3°C. The 3, 6 and 10 % hydrogels exhibited the endotherms at 39.2, 45.9 and 46.8°C respectively which was lower than that observed for the 8-arm-PEG-SH (51.7°C). The intermolecular crosslinking of the polymer chains results in reduced mobility (resulting in increased T_g), and these polymer chains cannot reorient to form a highly ordered crystalline structure (lowered melting point). The addition of glycerin, PVP and PEG 600 slightly lowered the endotherms of 3 %, 6 % and 10 % hydrogels when compared to hydrogels without additives (Fig. 4B). The hydrogels with PEG 600 showed an endotherm corresponding to it between 15.6 to 14.3°C in addition to the endotherm (37.9 to 38.9°C) corresponding to 8-arm-PEG-SH (Fig. 4B). The structural characteristics of both PEG hydrogel and dendrimer are seen in the dendrimer-PEG hydrogels.

3.6. Degradation of hydrogels

The hydrogels investigated in the current study are biodegradable in nature and their degradation was evaluated in simulated vaginal fluid and buffer as they are designed for intravaginal and intracervical application. The disulfide crosslinks in the hydrogels are introduced to aid its slow degradation and easy self washout from the body orifice. The female reproductive tract secretions are rich in glutathione and glutathione transferase and the GSH levels range between 28-284 mg in human cervical secretions[59, 60]. The disulfide linkage or crosslinks in the gel are cleavable in presence of GSH [61-63]. Thiol-disulfide exchange is a chemical reaction in which a thiolate group S^- attacks on one of the sulfur atom of a disulfide bond **-S-S-**. Under basic and mild acidic conditions GSH is known to act as thiolate moiety and it gets oxidized while cleaving the existing disulfide bonds. These reactions are favored at higher basic pH and the vaginal pH is low (3.8-4.5). It is therefore expected that *in-vivo* the disulfide bonds in gel would undergo a slow degradation at vaginal pH, in presence of GSH. The *in-vitro* experiment showed that hydrogels were stable upto 3 days upon exposure to GSH solution at a pH 4.0, and in simulated vaginal fluid, and did not show any signs of degradation as seen (Fig. S4 supporting information). After 72 h the gels started to degrade and erode in both the solutions this was reflected in ~0.24 % w/w reduction in the weight of the gels, and a further reduction in weight by ~0.44 % w/w over time (Fig. S5 supporting information). This is consistent with the *in-vivo* degradation pattern which is discussed in the subsequent sections. The chromatograms for the GSH solutions containing hydrogels did not show generation of any peaks until 50 h (data not shown). After 65 h the presence of few small peaks could be seen which is attributed to the breakdown of the gel into the smaller polymer components. The slow degradation of hydrogel is expected over time and would release the polymer components. The amine terminated dendrimers by themselves exhibit antibacterial activity by alteration of the bacterial cell wall [25]. The $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ dendrimers in present study have partially unmodified amine groups and these dendrimers are therefore expected to act as antibacterial agents. The antibacterial activity of partially PEGylated amine terminated dendrimers is well documented [24]. Hence the hydrogels of the present study are expected to exhibit dual antibacterial mechanism attributed to the slow release of the amoxicillin followed by release of partially amine terminated G4 PAMAM dendrimer.

3.7. Degree of swelling

The degree of swelling in hydrogels was measured gravimetrically by calculating the equilibrium swelling obtained by comparing the ratios of the weights of the dry and water-swollen hydrogels over the time course. The degree of swelling in hydrogels influences the pore size which affects the mechanical strength of the hydrogels and the drug release properties. The 3% hydrogel showed higher swelling when compared to that of 6% and 10% gel (Fig. S6 supporting information). The equilibrium swelling state was reached for the 3, 6 and 10% hydrogels within 10, 8 and 6 h respectively. The observed pattern is attributed to the increased cross-linking density in hydrogels containing higher polymer concentration. It was observed from the confocal microscopy that the crosslink density in 3% hydrogel was lower as compared to the 6 and 10% and the swelling results further support these results.

3.8. Drug loading efficiency

Amoxicillin was physically entrapped into the *in-situ* forming gels. Amoxicillin was dissolved in the 8-arm-PEG solution and mixed with the [(NH₂)₄₉-G4-(NH-PDP)₁₅] solution to form the gel. The theoretical amounts of drug used for entrapment were 0.50 mg in 200 µL of hydrogel formulation (3, 6 and 10%). The drug extracts from the hydrogel were quantified by reverse phase (RP) HPLC analysis monitoring elution with absorbance of 229 nm using water: acetonitrile as mobile phase. The amount of drug entrapped in the 3, 6 and 10 % w/v hydrogels was 52, 45 and 41% respectively. The 3% gels showed relatively higher drug loading efficiency over the 6 and 10% gels and this difference could be attributed to higher crosslinking density in gels with higher polymer concentration and reduced pore size as seen in Fig.3.

3.9. *In-vitro* drug release

The *in-vitro* drug release profiles from three different hydrogel formulations were studied using Franz diffusion cells. The plot of cumulative amount of drug released (mg/cm²) as a function of time (h) from the three different types of hydrogels is shown in Fig. 5A. The drug release plot shows that amoxicillin release was sustained for 260 h with a total release of 72 %, 63 %, 51 % from 3 %, 6 % and 10 % hydrogels respectively. A relatively slower drug release was observed from 10 % hydrogel when compared to 3 % hydrogel. These results are consistent with the lower swelling of the 10 % hydrogel which is attributed to the high crosslink density in polymer network obtained for higher polymer concentrations which lowers the pore size. The plot of percent drug released verses time was used to determine the release mechanism (Fig. 5B). The data (first 60 % of the amount release) was fitted to explain the release mechanism and pattern using the Peppas equation as follows

$$\frac{M_t}{M_\infty} = kt^n \quad (\text{eq. I})$$

Where M_t/M_∞ is the fraction of drug released, ' k ' is a kinetic (proportionality) constant dependent on the system, ' t ' is the time period for release, and ' n ' is the diffusion exponent indicative of the release mechanism for matrices of various shapes and swelling patterns. In the case of Fickian release, the exponent ' n ' has a limiting value of 0.50, 0.45, and 0.43 from slabs, cylinders, and spheres, respectively[64]. The values of ' n ' and ' k ' are inversely related, and a higher value of ' k ' suggests a burst release of drug from matrix. The values of diffusional exponent are shown in Table 2. At higher polymer concentration (10 %) the drug release mechanism seems to approach the Fickian diffusion with $n = 0.49$, while the lower polymer concentrations exhibit non Fickian release mechanism. One of the important functions of the gel is to provide extended release of the drug, which was evaluated using the Franz diffusion cell. This study shows that the drug is released by diffusion mechanism

from gels at higher concentration. This study also confirms that there is no dose dumping from the gel and it exhibits the extended release to exhibit local therapeutic efficacy[44-46].

Permeation parameters were obtained from the cumulative amounts of drug permeated (mg cm^{-2}) as a function of time (hours). The steady state flux (J) representing the absorption rate per unit area was determined from the slope of the linear portion of the plots. In all experiments same numbers of data points were taken to calculate the steady state flux. The permeability constant (P) was calculated according to Fick's first law of diffusion, based on the steady state flux and the applied drug concentration (C_i) on the donor side. The permeability coefficients were deduced by dividing the flux by the initial drug load (C_i) as shown in equation

$$J = \frac{dQ}{dt.A} \quad (\text{eq. II})$$

$$P = \frac{J}{C_i} \quad (\text{eq. III})$$

The flux, diffusional exponent and permeability coefficient are shown in Table 2. The flux and permeability was found to decrease with the increase in the polymer concentration. This is due to the increased crosslink density and lower swelling of the hydrogels at higher polymer content. The observed result is consistent with the lower drug release rate at higher polymer concentrations. This indicates that the dendrimer PEG-hydrogel forms a tight network as compared to the PEG crosslinked hydrogels. The dendrimer-PEG hydrogels of the present study are therefore expected to sustain the drug release efficiently.

3.10. *In-vivo* testing of hydrogel formulations in guinea pig model

Vaginal distribution, retention, biodegradation and tolerability of gels are important parameters to achieve sustained residence in the body cavity. The intravaginal gels of the present investigation are developed to treat the ascending genital infections during pregnancy. Since the gel is *in-situ* forming, permeation and transport of the gel (PEG and $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ polymers) across the fetal membranes into the fetus was investigated. The 10% w/v gels were used for *in-vivo* testing as these were found to sustain the drug release for longer times as compared to 3 and 6 % gels. The volume of the gel for intravaginal application was determined by injecting the samples 100 μL to 500 μL . The ideal volume for application was found to be 200 μL and any volume above that resulted in leaking of the gel material outside the vagina. Similar volumes for intravaginal gels in guinea pigs were reported [20]. The gels without formulation additives exhibited short residence times and were leaked out as brittle particles after 24 h. The gels with formulation additives (glycerin, PVP and PEG 600) were retained in the cervicovaginal region at least up to 72 h, the end point used in this protocol. The incorporation of PVP in the gels provides the mucoadhesive effect. Fig. 6 shows the presence of gel after 5, 12, 24 and 72 h of application. The visual examination revealed that 200 μL gel volume was sufficient to cover the cervicovaginal region. The gel could be seen in the cervicovaginal region in the early hours after application (5 and 12h) and the gel was retained in this region even at later time points (24 to 72 h). The gel was found to slowly degrade with change in morphology and the eroded material was seen on the fetal membranes of the pups positioned very close to the cervix (Fig. 7A). The gel was not seen on any other pup (fetus) positioned away from the cervix. It is interesting to note that the gels with disulfide bonds exhibited a slow degradation *in-vivo* at vaginal pH. This observation is similar to the *in-vitro* degradation study in simulated vaginal fluid with GSH at pH 4. The gel components remained on the surface of the fetal membranes without transport across the membranes (Fig. 7A and 7B).

The $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ dendrimer released due to degradation of the gel is not seen across the fetal membrane. The pups did not show traces of gel components on fur after removal of the fetal membranes (Fig. 7C) indicating that the gel does not cross across the fetal membranes and can be used for the selective local treatment of the pregnant mother without transfer to the fetus. Our previous *ex-vivo* studies in human fetal membranes showed that the transport of FITC labeled G4 PAMAM dendrimers is restricted across the membrane [65]. The results of the present *in-vivo* study combined with the previous *ex-vivo* study substantiate that the hydrogels formed using the $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and 8-arm-PEG-SH do not cross the fetal membranes and could be used for the selective local treatment of pregnant woman without transfer to the fetus. The pH of the vagina was tested after 5 h, 12 h and 24 h after application of the gel using the swabs, and no change in pH was observed after application of the gel. The gels are formed rapidly *in-situ* and they absorb the buffer in which they were formed without affecting the pH of the vagina. None of the animals showed any discomfort after application of gel, none of the animals aborted in 72 h. The visual examination of the vaginal tissues showed no signs of edema and irritation and the gels were well tolerated by the animals.

The histological evaluation of the uterus and cervicovaginal epithelial layer shows that the cell layer was not disrupted and no morphological changes were observed in the cells after 24 and 72 h treatment with hydrogels (Fig. 8). The epithelial layer of the control tissue and the 24 and 72 h tissue with hydrogel treatment appear comparable. There are no signs of sloughing of the epithelial cells into the lumen, inflammation or edema of the epithelium. The submucosal tissues after hydrogel treatment (24 and 72 h) did not show any signs of necrosis or massive infiltration of the inflammatory cells. The cervical tissues show presence of the superficial mucous cell layer and after treatment with hydrogels the tissues do not show any signs of sloughing of the superficial mucous layer.

No signs of atrophy of the epithelial cell layer or the superficial mucous layer were observed after the hydrogel treatment for 72 h. The animals treated with hydrogels did not show any signs of thickening of the mucous cell layer when compared to the control animal (Fig. 8). These results suggested that the animals were tolerant to the gels and no untoward reaction was exhibited. The residence of the gel on the mucified epithelial cells of the cervicovaginal region was further confirmed from the histological evaluation of immunohistofluorescence images (Fig. 9). The fluorescent gel comprising $[(\text{NH}_2)_{49}\text{-G4-(NH-FITC)}_2\text{-(NH-PDP)}_{15}]$ crosslinked with 8-arm-PEG-SH was used for this investigation and the cross sections of the vagina and cervix show the presence of fluorescent gel (green color) on the mucified epithelial layer (red) marked positive with anticytokeratin. The presence of gel is apparent at time points 24 and 72 h respectively. The immunohistofluorescence images of the *fetal* membrane and the uterus at 72 h do not show the presence of the gel across these tissues (Fig. 10), as seen by the absence of the fluorescent green. These results confirm that the gel components are primarily located on the epithelial surface of cervical region and do not cross into deeper tissue. The ascending bacterial infection causes chorioamnionitis which is associated with development of cerebral palsy, a motor disorder in children due to stimulation of proinflammatory cytokines causing white matter damage and fetal brain injury [66]. The local delivery of antibiotics in the cervicovaginal region is preferred therapy for the treatment of these infections.

The hydrogels exhibited long residence times of at least 72 h and were very well tolerated by the tissues. The constituent dendrimer of this hydrogel was not cytotoxic to human cervical epithelial and BV2 mouse microglial cells at the concentrations used in the topical application, as shown before [67]. In addition, PEGylation of the PAMAM dendrimer is expected to reduce the cytotoxicity of the dendrimer significantly [68]. The covalent linking of the dendrimer to the PEG overcomes the cytotoxicity associated with the dendrimer

which is well documented [17, 40]. These findings are significant as the dendrimers in the size range 5 to 6 nm do not cross the human fetal membranes which separate the extra-amniotic cavity and the fetus, and could be used for the local intravaginal delivery of pregnant woman, as we have reported recently [65]. The overall findings of the present study suggest that the proposed hydrogels offer an excellent degradable drug delivery system which exhibits sustained local delivery of the antibacterial agents intravaginally to the pregnant mother without transfer to the fetus.

4. Conclusions

Drug therapy during pregnancy is challenging, and effective ways to selectively treat the pregnant woman without affecting the fetus are always desired. Topical delivery of therapeutic agents is favored to treat ascending genital infections in pregnant women. Biodegradable *in-situ* forming hydrogels obtained by crosslinking of[(NH₂)₄₉-G4-(NH - PDP)₁₅] dendrimer and 8-arm-PEG via formation of disulfide bridges is described. Amoxicillin release from these hydrogels (3, 6 and 10% w/v) is sustained for more than 240 h and the release approaches Fickian diffusion pattern from the 10 % w/v hydrogels. The *in-vivo* evaluation of the hydrogels using pregnant guinea pig model shows that gels are very well tolerated by the animals and no signs of change in vaginal pH and erythema are observed up to 72 h. The gel volume of 100-200 μ l was found to sufficiently cover the entire cervicovaginal region as seen by visual examination. The gels exhibited a slow degradation *in-vivo* at the vaginal pH and the degraded gel was retained in the maternal tissues without transfer across the fetal membranes. These results were confirmed by visual and immunohistofluorescence images of tissues which showed that the gel is largely retained in the superficial mucified epithelial cells. The histopathological evaluation of the vaginal and the cervical tissues showed absence of epithelial cell edema, necrosis and infiltration of inflammatory cells in the subepithelial and submucosal tissues. There were no signs of sloughing of the superficial epithelial cell layer after application of the hydrogels. The morphology of the tissues treated with the hydrogels for 24 and 72 h was comparable to that of the control tissues. The overall results confirm that the gels were very well tolerated by the animals and none of the animals aborted in 72 h after application of gels. The *in-situ* forming hydrogels of the present invention offer therapeutic approaches to provide localized selective treatment of the pregnant woman with ascending genital infections without adverse effects to the fetus.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH/DHHS). We would like to thank Dr. Mihai Manitiu for his help in with SEM images and Dr. Bing Wang for help with animal experiments and Dr. C.J. Kim for the histopathological evaluations of the tissues.

References

1. Liu SQ, Ee PL, Ke CY, Hedrick JL, Yang YY. Biodegradable poly(ethylene glycol)-peptide hydrogels with well-defined structure and properties for cell delivery. *Biomaterials*. 2009; 30(8): 1453–1461. [PubMed: 19097642]
2. Gayet JC, Fortier G. High water content BSA-PEG hydrogel for controlled release device: Evaluation of the drug release properties. *J. Control. Rel.* 1996; 38:177–184.

3. Siemoneit U, Schmitt C, Alvarez-Lorenzo C, Luzardo A, Otero-Espinar F, Concheiro A, et al. Acrylic/cyclodextrin hydrogels with enhanced drug loading and sustained release capability. *Int. J. Pharm.* 2006; 312(1-2):66–74. 7. [PubMed: 16464549]
4. Nirmal HB, Bakliwal SR, Pawar SP. In-Situ gel: New trends in controlled and sustained drug delivery system. *Int J PharmTech Res.* 2010; 2:1398–1408.
5. Liu W, Griffith M, Li F. Alginate microsphere-collagen composite hydrogel for ocular drug delivery and implantation. *Journal of Materials Science: Materials in Medicine.* 2008; 19(11):3365–3371. [PubMed: 18545941]
6. Bilensoy E, Rouf MA, Vural I, Sen M, Hincal AA. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex. *AAPS PharmSciTech.* 2006; 7(2):E38. [PubMed: 16796356]
7. Miyazaki S, Suisha F, Kawasaki N, Shirakawa M, Yamatoya K, Attwood D. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. *J Control. Rel.* 1998; 56(1-3):75–83. 4.
8. Hubert P, Evrard B, Maillard C, Franzen-Detrooz E, Delattre L, Foidart JM, et al. Delivery of granulocyte-macrophage colony-stimulating factor in bioadhesive hydrogel stimulates migration of dendritic cells in models of human papillomavirus-associated (pre)neoplastic epithelial lesions. *Antimicrob. Agents Chemother.* 2004; 48(11):4342–4348. [PubMed: 15504863]
9. Ndesendo VM, Pillay V, Choonara YE, Buchmann E, Bayever DN, Meyer LC. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. *AAPS PharmSciTech.* 2008; 9(2):505–520. [PubMed: 18431651]
10. Martius J, Eschenbach DA. The role of bacterial vaginosis as a cause of amniotic fluid infection, chorioamnionitis and prematurity-a review. *Arch. Gynecol. Obstet.* 1990; 247:1–13. [PubMed: 2178562]
11. Romero R, Chaiworapongsa T, Espinoza J. Micronutrients and intrauterine infection, preterm birth and the fetal inflammatory response syndrome. *The Journal of nutrition.* 2003; 133(5 Suppl 2): 1668S–1673S. [PubMed: 12730483]
12. Ugwumadu A. Role of antibiotic therapy for bacterial vaginosis and intermediate flora in pregnancy. *Best practice & research.* 2007; 21(3):391–402.
13. Robinson R, Bologna W. Cervico-vaginal and reproductive system treatments using a bioadhesive polymer. *J. Control. Rel.* 1994; 28:88–94.
14. Valenta C, Kast CE, Harich I, Bernkop-Schnurch A. Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone. *J. Control. Rel.* 2001; 77(3):323–332. 13.
15. Richardson JL, Whetstone J, Fisher AN, Watts P, Farraj NF, Hinchcliffe M, et al. Gamma-scintigraphy as a novel method to study the distribution and retention of a bioadhesive vaginal delivery system in sheep. *J. Control. Rel.* 1996; 42:133–142.
16. Hardy E, Jimenes AL, de Padua KS, Zanevald LJD. Women's preferences for vaginal antimicrobial contraceptives, III: choice of a formulation, applicator and packaging. *Contraception.* 1998; 58:245–249. [PubMed: 9866007]
17. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. *Drug Discov Today.* 2010; 15(5-6):171–185. [PubMed: 20116448]
18. Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. *Antimicrob. Agents Chemother.* 2000; 44(9):2471–2474. [PubMed: 10952597]
19. Mumper RJ, Bell MA, Worthen DR, Cone RA, Lewis GR, Paull JR, et al. Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action. *Drug development and industrial pharmacy.* 2009; 35(5):515–524. [PubMed: 19040181]
20. Bernstein DI, Stanberry LR, Sacks S, Ayisi NK, Gong YH, Ireland J, et al. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. *Antimicrob. Agents Chemother.* 2003; 47(12):3784–3788. [PubMed: 14638483]
21. Patton DL, Sweeney Y. T. Cosgrove, McCarthy TD, Hillier SL. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. *Antimicrob. Agents Chemother.* 2006; 50(5):1696–1700. [PubMed: 16641437]

22. [website accessed on 07/10/2009] <http://clinicaltrials.gov/ct2/results?term%4SPL7013>
23. Calabretta MK, Kumar A, McDermott AM, Cai C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. *Biomacromolecules*. 2007; 8(6):1807–1811. [PubMed: 17511499]
24. Lopez AI, Reins RY, McDermott AM, Trautner BW, Cai C. Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. *Molecular bioSystems*. 2009; 5(10):1148–1156. [PubMed: 19756304]
25. Wang B, Navath RS, Menjoge AR, Balakrishnan B, Bellair R, Dai H, et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. *Int. J. Pharm.* 2010; 395(1-2):298–308. 16. [PubMed: 20580797]
26. Lebreton S, Newcombe N, Bradley M. Antibacterial single-bead screening. *Tetrahedron*. 2003; 59:10213–10222.
27. Cheng Y, Qu H, Ma M, Xu Z, Xu P, Fang Y, et al. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. *Eur. J. Med. Chem.* 2007; 42(7):1032–1038. [PubMed: 17336426]
28. Balogh L, Swanson DR, Tomalia DA, Hagnauer GL, McManus AT. Dendrimer-silver complexes and nanocomposites as antimicrobial agents. *Nano lett.* 2001; 1:18–21.
29. Devarakonda B, Li N, de Villiers MM. Effect of polyamidoamine (PAMAM) dendrimers on the in vitro release of water-insoluble nifedipine from aqueous gels. *AAPS PharmSciTech*. 2005; 6(3):E504–512. [PubMed: 16354011]
30. Unal B, Hedden RC. pH-dependent swelling of hydrogels containing highly branched polyamine macromonomers. *Polymer*. 2009; 50:905–912.
31. Wu X, Huang SW, Zhang JT, Zhuo RX. Preparation and characterization of novel physically cross-linked hydrogels composed of poly (vinyl alcohol) and amine terminated polyamidoamine dendrimer. *Macromol Biosci*. 2004; 4:71–75. [PubMed: 15468196]
32. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. *Nature Rev.* 2002; 1(12):977–985.
33. Hui D, Navath RS, Balakrishnan B, Guru BR, Mishra MK, Romero R, et al. Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers. *Future Medicine Nanomedicine*. 2010; 5:1317–1329.
34. Degoricija L, Bansal PN, Sontjens SH, Joshi NS, Takahashi M, Snyder B, et al. Hydrogels for osteochondral repair based on photocrosslinkable carbamate dendrimers. *Biomacromolecules*. 2008; 9(10):2863–2872. [PubMed: 18800810]
35. Desai PN, Yuan Q, Yang H. Synthesis and characterization of photocurable polyamidoamine dendrimer hydrogels as a versatile platform for tissue engineering and drug delivery. *Biomacromolecules*. 2010; 11(3):666–673. 8. [PubMed: 20108892]
36. Sontjens SH, Nettles DL, Carnahan MA, Setton LA, Grinstaff MW. Biodendrimer-based hydrogel scaffolds for cartilage tissue repair. *Biomacromolecules*. 2006; 7(1):310–316. [PubMed: 16398530]
37. Taleb MFA, Elsigeny SM, Ibrahim MM. Radiation synthesis and characterization of polyamidoamine dendrimer macromolecules with different loads of nickel salt for adsorption of some metal ion. *Rad Phy Chem*. 2007; 76:1612–1618.
38. Zhang JT, Huang SW, Zhuo RX. Temperature-sensitive polyamidoamine dendrimer/poly(N-isopropylacrylamide) hydrogels with improved responsive properties. *Macromol Biosci*. 2004; 4(6):575–578. 25. [PubMed: 15468250]
39. Creasas GC, Charalambidis VM, Zagotzidou E, Aravantinos DI. Untreated cervical infections, chorioamnionitis and prematurity. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 1995; 49(1):1–7. [PubMed: 9457977]
40. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. *Adv Drug Deliv Rev*. 2005; 57:2215–2237. [PubMed: 16297497]
41. Navath RS, Menjoge AR, Wang B, Romero R, Kannan S, Kannan RM. Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications. *Biomacromolecules*. 2010; 11(6):1544–1563. 14. [PubMed: 20415504]

42. Menjoge AR, Kulkarni MG. Mechanistic investigations of phase behavior in Eudragit E blends. *Int. J. Pharm.* 2007; 343(1-2):106–121. 1. [PubMed: 17587518]
43. Gupta H, Sharma A. Ion activated bioadhesive in situ gel of clindamycin for vaginal application. *Int J Drug Delivery.* 2009; 1:32–40.
44. Siewert M, Brown CK, Dressman J, Shah VP. FIP /AAPS Guidelines to Dissolution / in-vitro release testing of Novel / Special Dosage forms. *AAPS PharmSciTech.* 2003; 4(1) Article 7.
45. Neves JD, Bahia MF. Gels as vaginal drug delivery systems. *Int. J. Pharm.* 2006; 318:1–14. [PubMed: 16621366]
46. Gupta H, Sharma A. Ion activated bioadhesive in situ gel of clindamycin for vaginal application. *Int. J. Drug Delivery.* 2009; 1(1):32–40.
47. Mijovic J, Ristic S, Kenny J. Dynamics of six generations of PAMAM dendrimers as studied by dielectric relaxation spectroscopy. *Macromolecules.* 2007; 40:5212–5221.
48. Huh KM, Bae YH. Synthesis and characterization of poly(ethylene glycol)/poly(L lactic acid) alternating multiblock copolymers. *Polymer.* 1999; 40(22):6147–6155.
49. Qiao C, Jiang S, Dong D, Ji X, An L, Jiang B. The Critical Lowest Molecular Weight for PEG to Crystallize in Cross-Linked Networks. *Macromol Rapid Commun.* 2004; 25:659–663.
50. Geonotti AR, Katz DF. Compartmental transport model of microbicide delivery by an intravaginal ring. *J.Pharm.Sci.* 2010; 99(8):3514–3521. [PubMed: 20222027]
51. Barnhart K, Kulp JL, Rosen M, Shera DM. A randomized trial to determine the distribution of four topical gel formulations in the human vagina. *Contraception.* 2009; 79(4):297–303. [PubMed: 19272499]
52. Ash, MAI. Handbook of preservatives. Synapse Information Resources, Inc; Endicott, New York: 2004.
53. Uglea, CV. Oligomer technology and applications. CRC press; Boca Raton, FL: 1998.
54. Jones DS, Irwin CR, Woolfson AD, Djokic J, Adams V. Physicochemical characterization and preliminary in vivo efficacy of bioadhesive, semisolid formulations containing flurbiprofen for the treatment of gingivitis. *J. Pharm Sci.* 1999; 88(6):592–598. [PubMed: 10350494]
55. Ceschel GC, Maffei P, Borgia S, Lombardi, Ronchi C, Rossi S. Development of a mucoadhesive dosage form for vaginal administration. *Drug Dev Ind Pharm.* Jul; 2001 27(6):541–547. [PubMed: 11548861]
56. Chang JY, Oh YK, Choi HG, Kim YB, Kim CK. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. *Int. J. Pharm.* 2002; 241(1):155–163. 8. [PubMed: 12086731]
57. Chu JS, Amidon GL, Weiner ND, Goldberg AH. Mixture experimental design in the development of a mucoadhesive gel formulation. *Pharm. Reser.* 1991; 8(11):1401–1407.
58. Park H, Robinson JR. Physicochemical properties of water insoluble polymers important to mucin/epithelial adhesion. *J. Control. Rel.* 1985; 2:47–57.
59. Salmen JJ, Skufca F, Matt A, Gushansky G, Mason A, Gardiner CS. Role of glutathione in reproductive tract secretions on mouse preimplantation embryo development. *Biol Reprod.* 2005; 73(2):308–314. [PubMed: 15829622]
60. Gardiner CS, Salmen JJ, Brandt CJ, Stover SK. Glutathione is present in reproductive tract secretions and improves development of mouse embryos after chemically induced glutathione depletion. *Biol Reprod.* 1998; 59(2):431–436. [PubMed: 9687318]
61. Navath RS, Wang B, Kannan S, Romero R, Kannan RM. Stimuli-responsive star poly(ethylene glycol) drug conjugates for improved intracellular delivery of the drug in neuroinflammation. *J. Control. Release.* 2010; 142(3):447–456. 19. [PubMed: 19896998]
62. Kurtoglu YE, Navath RS, Wang B, Kannan S, Romero R, Kannan RM. Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. *Biomaterials.* 2009; 30(11):2112–2121. [PubMed: 19171376]
63. Navath RS, Kurtoglu YE, Wang B, Kannan S, Romero R, Kannan RM. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. *Bioconjugate chemistry.* 2008; 19(12):2446–2455. [PubMed: 19053299]

64. Menjoge AR, Kulkarni MG. Blends of reverse enteric polymer with Enteric and pH-independent polymers: mechanistic investigations for tailoring drug release. *Biomacromolecules*. 2007; 8(1): 240–251. [PubMed: 17206813]
65. Menjoge AR, Navath RS, Asad A, Kannan S, Kim CJ, Romero R, Miller R, Kannan RM. Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates. *Biomaterials*. 2010; 31(18):5007–5021. [PubMed: 20346497]
66. Patrick LA, Gaudet LM, Farley AE, Rossiter JP, Tomalty LL, Smith GN. Development of a guinea pig model of chorioamnionitis and fetal brain injury. *Am. J. Obstet. Gynecol.* 2004; 191(4):1205–1211. [PubMed: 15507942]
67. Wang B, Navath RS, Menjoge AR, Balakrishnan B, Bellair R, Dai H, Romero R, Kannan S, Kannan RM. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. *Int. J. Pharm.* 2010; 395(1-2):298–308. [PubMed: 20580797]
68. Kim Y, Klutz AM, Jacobson KA. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. *Bioconjugate Chem.* 2008; 19:1660–1672.




Fig. 1. The DSC thermogram of $[(\text{NH}_2)_{49}\text{-G4}\text{-(NH-PDP)}_{15}]$ shows the T_g at 21.4°C and an endotherm at 109.6°C . The increase in T_g to 21.4°C from -28°C indicates modification of amine terminated PAMAM dendrimer with PDP groups.




Fig. 2. The SEM images of dendrimer $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ crosslinked with 8-PEG-SH gel (A) 200 μm (200x) (B) 50 μm (1000x) (C) 20 μm (2000x). These gels were dehydrated by lyophilization.




Fig. 3.

Hydrogel labeled with FITC to demonstrate the pore structure of the gel. By introducing the different concentration of polymers (dendrimer $[(\text{NH}_2)_{49}\text{-G4-(NH-PDP)}_{15}]$ and 8-PEG-SH) in the hydrogels, crosslinking density gradually increased by increasing the concentration of polymer. 3% hydrogel (A), 6% hydrogel (B) 10% hydrogel (C) shows the crosslinking network changes with increasing polymer concentration, scale bar represents 50 μm .




Fig. 4. The DSC thermograms for the 3, 6 and 10 % dendrimer-PEG hydrogels. (A) Hydrogels without formulation additives (absence of glycerin, PVP and PEG600), The 8-arm-PEG-SH (e) shows an endotherm at 51.7°C, which is lowered on crosslinking with [(NH₂)₄₉-G₄-(NH-PDP)₁₅] as seen in curves (b), (c) and (d) for 3, 6 and 10% hydrogels respectively (B) Hydrogels with formulation additives (glycerin, PVP and PEG 600). In addition to the endotherms corresponding to 8-arm-PEG-SH (37.9 to 38.9°C) in hydrogels, an endotherm for PEG 600 is seen between 15.6 to 14.3 °C.




Fig. 5. (A) Cumulative amount of amoxicillin released with respect to time (h) across per cm^2 area for 3, 6 and 10% hydrogels and (B) cumulative amount of amoxicillin released with respect to time. The release mechanism was found to be non-fickian for 3 and 6% hydrogels while for 10% hydrogels it approached fickian diffusion. All the experiments were carried out in triplicate and the data in the plots represents the mean of these and the error bars represent the standard deviations (+/-).




Fig. 6. Intravaginal and intracervical application of *in-situ* forming dendrimer-PEG hydrogels in the pregnant guinea pigs. The green arrows mark the presence of hydrogel on the tissue (A) day 1: hydrogel after 5h of application, (B) day 1: hydrogel after 12 h of application (C) day 2 after hydrogel application (D) day 3 after hydrogel application, where 'C' = cervix, V= vaginal cavity, U = uterus with pups. The hydrogel is retained in the cervix and vaginal cavity for 2 days and on day 3 it's seen largely in the vaginal cavity of pregnant guinea pigs.




Fig. 7. The dendrimer-PEG hydrogels after intravaginal and intracervical application in pregnant guinea pigs do not cross the fetal membrane and enter into the gestational (sac) cavity. (A) day 3: hydrogel seen on the fetal membrane of the pup positioned close to the cervix, the green arrows mark the presence of fetal membrane on the pup, the black arrows show the presence of gel outside of the fetal membrane (B) the pup covered in fetal membrane with hydrogel on top of the fetal membrane (C) the pup after removal of the fetal membrane showing no signs of hydrogel on the fur or inside the fetal membrane.




Fig.8.

The hemotoxylin and eosin stained histological sections of uterus (U), upper cervix (Ucx) and cervix (Cx) of guinea pig treated with the hydrogels for 24 h and 72 h (n=3 per group). The epithelial cell lining in all the tissues is intact and does not show any signs of inflammation and edema. The submucosa of hydrogel treated cervix after 24 and 72 h is comparable to the control. None of the tissues showed any signs of epithelial sloughing, necrosis in the submucosa or massive infiltration of inflammatory cells. EP = epithelial cells, SE = subepithelium, SM = submucosa, M = muscular layer EGC = endometrial gland cells, UC= uterus control, U24 and 72h = hydrogel treated uterus 24 and 74h, UCxC = control upper cervix, UCx24 and 72h = hydrogel treated upper cervix 24 and 74h, Cx-C = cervix control, Cx24 and 72h = hydrogel treated cervix 24 and 74h (40x magnification).




Fig.9.

The confocal images of the cervical region of pregnant guinea pigs treated with hydrogels for 24 and 72 h. The *in-situ* forming hydrogel comprising $[(\text{NH}_2)_{47}\text{-G4-(NH-FITC)}_2(\text{NH-PDP})_{15}]$ crosslinked with 8-arm-PEG-SH was applied to the cervicovaginal region. The hydrogel (green color) is seen on the surface of the mucosal layer (red color). The confocal images after 24 and 72 h confirm the presence of the gel on the tissue surface. The nuclei for all cells are stained blue with DAPI. There is no sign of the degraded gel into the subepithelial or submucosal layers. EP=epithelial layer, SE= subepithelial layer, ML= mucified epithelial layer.





Fig.10.

The confocal images of the fetal membrane and uterus of guinea pigs treated with hydrogels for 72 h. The *in-situ* forming hydrogel comprising $[(\text{NH}_2)_{47}\text{-G4-(NH-FITC)}_2(\text{NH-PDP})_{15}]$ crosslinked with 8-arm-PEG-SH was applied to the cervicovaginal region. The cross section of the uterus and the fetal membrane do not show presence of hydrogel or degraded hydrogel across the tissue.

**Scheme 1.**

Schematic representation of the hydrogel formation. The thiol-terminated 8-arm-PEG (20 kDa) formed gel at pH 7.4 by reacting with the thiopyridyl terminations of the $[(NH_2)_4-G-(NH-PDP)_{15}]$ resulting in disulfide linkages.

Table 1

Hydrogel compositions and stoichiometric ratio between thiopyridyl and thiol groups

% Hydrogel	Hydrogel volume	Weight of polymer and ratio (1:1)	Stoichiometric ratio of thiopyridyl to thiol groups	Gelation Time (s)	Polymer content
3%	200 μ L	[(NH ₂) ₄₉ -G4-(NH-PDP) ₁₅] (3mg) + PEG-SH(3 mg)(1:1)	(2:1)	30	3%
6%	200 μ L	[(NH ₂) ₄₉ -G4-(NH-PDP) ₁₅] (3mg) + PEG-SH(3 mg)(1:1)	(2:1)	20	6%
10	200 μ L	[(NH ₂) ₄₉ -G4-(NH-PDP) ₁₅] (3mg) + PEG-SH(3 mg)(1:1)	(2:1)	<10	10%

Table 2Determination of flux, diffusional exponent (n) and permeability coefficient for hydrogels

% w/v Hydrogels	Flux (J) (mg cm⁻² s⁻¹) × 10⁻⁷	Diffusion exponent (n)	Permeability Coefficient (P) (cm. h⁻¹) × 10⁻⁶
3%	4.72	0.20	1.81
6 %	4.16	0.25	1.85
10 %	3.88	0.49	1.89